TY - JOUR
T1 - Impact of network treatment in patients with resected pancreatic cancer on use and timing of chemotherapy and survival
AU - Hopstaken, Jana S.
AU - Vissers, Pauline A. J.
AU - Quispel, Rutger
AU - de Vos-Geelen, Judith
AU - Brosens, Lodewijk A. A.
AU - de Hingh, Ignace H. J. T.
AU - Van der Geest, Lydia G.
AU - Besselink, Marc G.
AU - van Laarhoven, Kees J. H. M.
AU - Stommel, Martijn W. J.
AU - Dutch Pancreatic Cancer Group
PY - 2023/5/5
Y1 - 2023/5/5
N2 - Background Centralization of pancreatic cancer surgery aims to improve postoperative outcomes. Consequently, patients with pancreatic cancer may undergo pancreatic surgery in an expert centre and adjuvant chemotherapy in a local hospital (network treatment). The aim of this study was to assess whether network treatment has an impact on time to chemotherapy, failure to complete adjuvant chemotherapy, and survival. Second, whether these parameters varied between pancreatic networks was studied. Methods This retrospective study included all patients diagnosed with non-metastatic pancreatic ductal adenocarcinoma who underwent pancreatic surgery and adjuvant chemotherapy, registered in the Netherlands Cancer Registry (2015-2020). Time to chemotherapy was defined as the time between surgery and the start of adjuvant chemotherapy. Completion of adjuvant chemotherapy was defined as the receipt of 12 cycles of FOLFIRINOX or six cycles of gemcitabine. Analysis was performed with linear mixed models and multilevel logistic regression models. Cox regression analyses were performed for survival. Results In total, 1074 patients were included. Network treatment was observed in 468 patients (43.6 per cent) and was not associated with longer time to chemotherapy (0.77 days, standard error (s.e.) 1.14, P = 0.501), failure to complete adjuvant chemotherapy (odds ratio (OR) = 1.140, 95 per cent c.i. 0.86 to 1.52, P = 0.349), and overall survival (hazards ratio (HR) = 1.04, 95 per cent c.i. 0.88 to 1.22, P = 0.640). Significant variation between the networks was observed for time to chemotherapy (range 40.5-63 days, P < 0.0001) and completion of adjuvant chemotherapy (range 19-52 per cent, P = 0.030). Adjusted for case mix, time to chemotherapy significantly differed between networks. Conclusion In this nationwide analysis, network treatment in patients with resected pancreatic cancer was not associated with longer time to chemotherapy, failure to complete adjuvant chemotherapy, and worse survival. Significant variation between pancreatic cancer networks was found for time to chemotherapy.This study shows that 44 per cent of all patients with pancreatic cancer treated with surgery and adjuvant chemotherapy undergo these in two hospitals (network treatment) instead of one pancreatic centre. It was hypothesized that network treatment, in which a patient is transferred from a referring hospital to a pancreatic centre, could be associated with the use and timing of adjuvant chemotherapy. In this study we have shown that network treatment does not negatively impact these outcomes.
AB - Background Centralization of pancreatic cancer surgery aims to improve postoperative outcomes. Consequently, patients with pancreatic cancer may undergo pancreatic surgery in an expert centre and adjuvant chemotherapy in a local hospital (network treatment). The aim of this study was to assess whether network treatment has an impact on time to chemotherapy, failure to complete adjuvant chemotherapy, and survival. Second, whether these parameters varied between pancreatic networks was studied. Methods This retrospective study included all patients diagnosed with non-metastatic pancreatic ductal adenocarcinoma who underwent pancreatic surgery and adjuvant chemotherapy, registered in the Netherlands Cancer Registry (2015-2020). Time to chemotherapy was defined as the time between surgery and the start of adjuvant chemotherapy. Completion of adjuvant chemotherapy was defined as the receipt of 12 cycles of FOLFIRINOX or six cycles of gemcitabine. Analysis was performed with linear mixed models and multilevel logistic regression models. Cox regression analyses were performed for survival. Results In total, 1074 patients were included. Network treatment was observed in 468 patients (43.6 per cent) and was not associated with longer time to chemotherapy (0.77 days, standard error (s.e.) 1.14, P = 0.501), failure to complete adjuvant chemotherapy (odds ratio (OR) = 1.140, 95 per cent c.i. 0.86 to 1.52, P = 0.349), and overall survival (hazards ratio (HR) = 1.04, 95 per cent c.i. 0.88 to 1.22, P = 0.640). Significant variation between the networks was observed for time to chemotherapy (range 40.5-63 days, P < 0.0001) and completion of adjuvant chemotherapy (range 19-52 per cent, P = 0.030). Adjusted for case mix, time to chemotherapy significantly differed between networks. Conclusion In this nationwide analysis, network treatment in patients with resected pancreatic cancer was not associated with longer time to chemotherapy, failure to complete adjuvant chemotherapy, and worse survival. Significant variation between pancreatic cancer networks was found for time to chemotherapy.This study shows that 44 per cent of all patients with pancreatic cancer treated with surgery and adjuvant chemotherapy undergo these in two hospitals (network treatment) instead of one pancreatic centre. It was hypothesized that network treatment, in which a patient is transferred from a referring hospital to a pancreatic centre, could be associated with the use and timing of adjuvant chemotherapy. In this study we have shown that network treatment does not negatively impact these outcomes.
KW - NATIONWIDE CENTRALIZATION
KW - ADJUVANT CHEMOTHERAPY
KW - SURGERY
KW - ADENOCARCINOMA
KW - LESSONS
KW - CARE
U2 - 10.1093/bjsopen/zrad006
DO - 10.1093/bjsopen/zrad006
M3 - Article
C2 - 37151083
SN - 2474-9842
VL - 7
JO - BJS Open
JF - BJS Open
IS - 3
M1 - zrad006
ER -